Nathalie Steinhoff

Nathalie Steinhoff

Auto-generated profile, based on publicly available information

Nathalie Steinhoff

Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
GLGabrielle Leclercq-Cohen
Gabrielle Leclercq-Cohen
NSNathalie Steinhoff
Nathalie Steinhoff
LSLlucia Albertí Servera
Llucia Albertí Servera
SNSina Nassiri
Sina Nassiri
SDSabrina Danilin
Sabrina Danilin
MBMarina Bacac
Marina Bacac
Purpose: Target-dependent TCB activity can result in the strong and systemic release of cytokines that may develop into cytokine release syndrome (CRS), highlighting the need to understand and prevent this complex clinical syndrome. Experimental Design: We explored the cellular and molecular players involved in TCB-mediated cytokine release by single-cell RNA-sequencing of whole blood treated with CD20-TCB together with bulk RNA-sequencing of endothelial cells exposed to TCB-induced cytokine release. We used the in vitro whole blood assay and an in vivo DLBCL model in immunocompetent humanized mice to assess the effects of dexamethasone, anti-TNFα, anti-IL6R, anti-IL1R, and inflammasome inhibition, on TCB-mediated cytokine release and antitumor activity. Results: Activated T cells release TNFα, IFNγ, IL2, IL8, and MIP-1β, which rapidly activate monocytes, neutrophils, DCs, and NKs along with surrounding T cells to amplify the cascade further, leading to TNFα, IL8, IL6, IL1β, MCP-1, MIP-1α, MIP-1β, and IP-10 release. Endothelial cells contribute to IL6 and IL1β release and at the same time release several chemokines (MCP-1, IP-10, MIP-1α, and MIP-1β). Dexamethasone and TNFα blockade efficiently reduced CD20-TCB–mediated cytokine release whereas IL6R blockade, inflammasome inhibition, and IL1R blockade induced a less pronounced effect. Dexamethasone, IL6R blockade, IL1R blockade, and the inflammasome inhibitor did not interfere with CD20-TCB activity, in contrast to TNFα blockade, which partially inhibited antitumor activity. Conclusions: Our work sheds new light on the cellular and molecular players involved in cytokine release driven by TCBs and provides a rationale for the prevention of CRS in patients treated with TCBs. See related commentary by Luri-Rey et al., p. 4320

25 November 2025
Verified
Other
Open access
GLGabrielle Leclercq-Cohen
Gabrielle Leclercq-Cohen
NSNathalie Steinhoff
Nathalie Steinhoff
LSLlucia Albertí Servera
Llucia Albertí Servera
SNSina Nassiri
Sina Nassiri
SDSabrina Danilin
Sabrina Danilin
MBMarina Bacac
Marina Bacac
Supplementary Figure S5. Overview of GO Biological process pathways found enriched in A. CD4+ T cells (6 hrs), B. CD8+ T cells (6 hrs), C. monocytes (6 hrs) and D. neutrophils (4 hrs) after treatment with 0.2 μg/mL CD20-TCB.

25 November 2025
Verified
Other
Open access
GLGabrielle Leclercq-Cohen
Gabrielle Leclercq-Cohen
NSNathalie Steinhoff
Nathalie Steinhoff
LSLlucia Albertí Servera
Llucia Albertí Servera
SNSina Nassiri
Sina Nassiri
SDSabrina Danilin
Sabrina Danilin
MBMarina Bacac
Marina Bacac
Supplementary Figure S12. Individual tumor growth curves for each treatment group. OCI-Ly18 (DLBCL)-bearing humanized NSG mice were pre-treated with 30 mg/kg Gazyva (Gpt, grey arrow) and treated weekly with escalating doses of CD20-TCB (0.5 mg/kg, 1 mg/kg, 2 mg/kg, red arrows). Adalimumab (25 mg/kg, orange arrow, TNF-α blockade) and tocilizumab (10 mg/kg, green arrow, IL-6R blockade) were given 1 day and 1 hour before the first CD20-TCB infusion. Dexamethasone (1 mg/kg, blue arrow) was given 1 hour prior each therapy. Anakinra (10 mg/kg, purple arrow, IL-1R blockade) and the NLRP3 inhibitor (20 mg/kg, light blue arrow) were administered 1 hour before, 4 hrs and 24 hrs after the first CD20-TCB infusion as well as 1 hr before and 4 hrs after the second CD20-TCB treatment. Individual tumor growth curves for each treatment group.

25 November 2025
Verified
Other
Open access
GLGabrielle Leclercq-Cohen
Gabrielle Leclercq-Cohen
NSNathalie Steinhoff
Nathalie Steinhoff
LSLlucia Albertí Servera
Llucia Albertí Servera
SNSina Nassiri
Sina Nassiri
SDSabrina Danilin
Sabrina Danilin
MBMarina Bacac
Marina Bacac
Supplementary Figure S8. Single cell RNA-sequencing of whole blood treated with 0.2 μg/mL CD20-TCB was performed using the BD Rhapsody platform.

25 November 2025
Verified
Other
Open access
GLGabrielle Leclercq-Cohen
Gabrielle Leclercq-Cohen
NSNathalie Steinhoff
Nathalie Steinhoff
LSLlucia Albertí Servera
Llucia Albertí Servera
SNSina Nassiri
Sina Nassiri
SDSabrina Danilin
Sabrina Danilin
MBMarina Bacac
Marina Bacac
Supplementary Figure S3. Identification of an interacting B and T cells cluster by scRNA sequencing of human whole blood treated with 0.2 μg/mL CD20-TCB using the BD Rhapsody platform.

25 November 2025
Verified
Other
Open access
GLGabrielle Leclercq-Cohen
Gabrielle Leclercq-Cohen
NSNathalie Steinhoff
Nathalie Steinhoff
LSLlucia Albertí Servera
Llucia Albertí Servera
SNSina Nassiri
Sina Nassiri
SDSabrina Danilin
Sabrina Danilin
MBMarina Bacac
Marina Bacac
Supplementary Figure S10. Single cell RNA-sequencing of whole blood treated with 0.2 μg/mL CD20-TCB was performed using the BD Rhapsody platform